How Lurbinectedin Targets Tumor Cells
Lurbinectedin binds to DNA in tumor cells, forming covalent adducts in the minor groove. This blocks double-strand DNA repair enzymes like PARP1 and PARP2, trapping them on DNA and causing replication fork collapse. The result is accumulation of double-strand breaks, cell cycle arrest in S phase, and apoptosis, primarily in rapidly dividing cancer cells.[1][2]
Mechanism in Small Cell Lung Cancer (SCLC)
Approved for metastatic SCLC after platinum failure, lurbinectedin inhibits transcription in tumor cells with high MYCN amplification—a common SCLC driver. It evicts elongating RNA polymerase II from promoter-proximal pause sites, halting gene expression needed for tumor survival. This effect is more pronounced in SCLC than other cancers due to their transcriptionally active state.[1][3]
Effects on the Tumor Microenvironment
Beyond direct cytotoxicity, lurbinectedin reduces tumor-associated macrophages (TAMs) and tumor blood vessels in preclinical models. It downregulates VEGF and CCR2 expression, clearing immunosuppressive MDSCs and improving T-cell infiltration, which enhances antitumor immunity.[2][4]
How It Differs from Platinum Chemotherapy
Unlike platinums, which cause bulky DNA adducts repaired by nucleotide excision repair (NER), lurbinectedin targets NER-deficient cells more selectively. Tumors resistant to platinums often retain sensitivity to lurbinectedin because it induces transcription-coupled repair stress rather than interstrand crosslinks.[1][5]
Resistance Mechanisms in Tumor Cells
Resistance emerges via increased drug efflux (ABCB1 pumps), enhanced DNA repair (upregulated NER genes like ERCC1), or SLFN11 downregulation—the primary sensor of lurbinectedin-induced damage. SLFN11-low tumors show innate resistance, guiding potential combination strategies with PARP inhibitors.[3][6]
Clinical Response Timelines and Tumor Shrinkage
In trials, tumor responses occur within 6-12 weeks, with median progression-free survival of 3.5 months in SCLC. PET-CT scans show rapid metabolic shutdown in responders, correlating with DNA damage markers like gamma-H2AX.[5]
[1]: FDA Label for Zepzelca (lurbinectedin)
[2]: Trigo et al., Lancet Oncology (2020) - Lurbinectedin mechanism review
[3]: Kawase et al., Cancer Discovery (2021) - Transcriptional effects in SCLC
[4]: Intrevado et al., Clin Cancer Res (2021) - Microenvironment modulation
[5]: Farago et al., J Clin Oncol (2019) - Phase II trial data
[6]: Colic et al., Cancer Cell (2020) - SLFN11 and resistance